SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes

Completed

• Conditions: COVID-19 Infection

• Registration Number: NCT04964024
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e. in the most vulnerable population for developing severe forms of the disease.

Residents and health professionals in 9 nursing homes (NHs) with SaRS-Cov-2 antibodies detection after exposure (either COVID-19 or vaccine) All biological tests were performed in the frame of the standard care of residents and health professionals and all participants did not express opposition for using anonymously their data for the purpose of this academic analysis. In addition all Directors and Physicians of these NHs accepted to participate in this study

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-06-26
• Study First Submitted QC: 2021-07-12
• Study Start: 2021-07-15
• Study First Posted: 2021-07-15
• Primary Completion: 2022-05-15
• Study Completion: 2022-05-15
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-18
• Last Update Posted: 2022-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1293

Inclusion Criteria

For Residents:

• Living in one of the 9 Nursing Homes that participate in this study
• Having a SARS-COV-2 post vaccination serology.
• Having no objection for using the results of the serology for the purpose of this analysis

For Health Professionals:

• Working in one of the 9 Nursing Homes that participate in this study,
• Having a SARS-COV-2 post vaccination serology.
• Having no objection for using the results of the serology for the purpose of this analysis

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Levels of SARS-COV-2 antibodies	Through study completion average 6 months Retrospective analysis	Study of the SARS-COV-2 antibodies according to the history of COVID-19 and vaccinal status in Nursing Home residents and in health professionals

Trial Locations

Locations (1)

CHRU de Nancy, Université de Lorraine; 🇫🇷 Vandoeuvre les Nancy, US And Canada Only, France